Clinical Trials Arena on MSN
IntraBio’s ataxia-telangiectasia drug meets endpoints in pivotal trial
If approved, levacetylleucine could become the first therapy on the market for ataxia-telangiectasia.
Phase 3 trial results show levacetylleucine improves SARA scores in patients with the rare disorder ataxia-telangiectasia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results